- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types

More here:
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

Read more from the original source:
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

Financial agenda for 2025

Original post:
Correction: GUERBET : Financial agenda for 2025

U.S. Department of Health and Human Services (HHS) office, BARDA, awards Micron $2 million to continue its work on broadly-protecting avian and seasonal flu vaccines U.S. Department of Health and Human Services (HHS) office, BARDA, awards Micron $2 million to continue its work on broadly-protecting avian and seasonal flu vaccines

Read more:
Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.A.).

Go here to read the rest:
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET.

View post:
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) regarding the clinical development of its partnered muscarinic agonist portfolio. These updates were presented by Neurocrine at the 43rd Annual J.P. Morgan Healthcare Conference. The update presented by Neurocrine included the following information:

Follow this link:
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option

Read the original:
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data

See the rest here:
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

— Indication expands to include treatment-naïve patients —

Read more:
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

MEDIA RELEASE

Visit link:
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Ad hoc announcement pursuant to Art. 53 LR

Visit link:
Idorsia publishes an invitation to a bondholder meeting

Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

Follow this link:
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

See the original post here:
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy...

School of Medicine professor receives grant to study improved cancer treatments  Mercer University

See the article here:
School of Medicine professor receives grant to study improved cancer treatments - Mercer University

Can The Heart Heal Itself? Expert Explains Breakthroughs In Cardiac Regeneration  Onlymyhealth

Link:
Can The Heart Heal Itself? Expert Explains Breakthroughs In Cardiac Regeneration - Onlymyhealth

Skip the Botox and Try One of These Growth Factor Serums Instead  ELLE

See the original post here:
Skip the Botox and Try One of These Growth Factor Serums Instead - ELLE

FDA Grants Orphan Drug Designation to IPS HEARTs GIVI-MPC Stem Cell Therapy for Becker Muscular Dystrophy  Business Wire

View original post here:
FDA Grants Orphan Drug Designation to IPS HEARTs GIVI-MPC Stem Cell Therapy for Becker Muscular Dystrophy - Business Wire

GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy  RegMedNet

See the rest here:
GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy -...

RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference.

Read the original:
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference